+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07045896

Fucoidan Treatment Added to Conventional Therapy for Adults With Active Rheumatoid Arthritis Multicenter, Open-label Study Evaluating Effects Over 12 Weeks

Led by Peking University People's Hospital · Updated on 2026-04-17

40

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the potential therapeutic effects of fucoidan, an inhibitor of scavenger receptor-A SR-A, in adults with active rheumatoid arthritis RA who have had an inadequate response to conventional treatments. RA is a chronic autoimmune disease marked by joint damage and autoantibody production, and elevated SR-A levels have been linked to disease progression. This multicenter, single-arm, open-label trial aims to provide original clinical data by enrolling 40 patients for a 12-week follow-up period to evaluate clinical symptoms, laboratory markers, and disease activity. Participants will continue their existing conventional RA treatments while taking 2000 mg of oral fucoidan twice daily for 12 weeks. Fucoidan is provided as size-0 gelatin capsules containing 1000 mg of fucoidan powder each. This add-on therapy will be systematically assessed throughout the treatment period to monitor its impact on disease progression and activity. Patients will undergo regular evaluations including clinical assessments and laboratory tests to measure disease activity and response to treatment. The primary outcome is the proportion of patients achieving the American College of Rheumatology 20% improvement criteria ACR20 at Week 12. Secondary outcomes include remission rates by Disease Activity Score in 28 joints using ESR, changes in clinical disease activity indices, and response rates according to other established RA criteria. Safety and adherence will also be monitored during the study period.

CONDITIONS

Brief Title

Fucoidan in the Treatment of Active Rheumatoid Arthritis

Research Team

L

Liling Xu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here